Effect of Dose of Buglossoides Oil on EPA Accrual and on the Inflammatory Response
Study of the Effect of Dose of Buglossoides Arvensis Oil on Eicosapentaenoic Acid Accrual and on the Inflammatory Response
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Brunswick
-
Moncton, New Brunswick, Canada, E1A 3E9
- Universite de Moncton
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or non-pregnant women, using an effective form of birth control (such as oral contraceptives, injectable contraceptives or the barrier method such as a intrauterine device (IUD) with a spermicide, a diaphragm with a spermicide, a condom with a spermicide or a sponge with a spermicide) for at least 3 months prior to entry into the study and continuing during participation in the study.
- 18 to 65 years of age, inclusive.
- Body mass index (BMI) 18 - 39.9 kg/m2
- Subject is willing to avoid alcohol consumption for 24h prior to every clinic visit.
- The subject will not modify smoking habits during supplementation period.
- No significant medical conditions that in the opinion of the qualified physician, would preclude the subject's participation in the study.
- Signed informed consent.
- Willing to follow all study procedures including study visits, fasting blood draws, stable body weight, normal eating habits, current activity level, and compliance with study preparation.
- Willing to not consume fish, crustaceans and shellfish for the duration of the study.
Exclusion Criteria:
- Pregnancy or lactation. Women trying to conceive. Women who will try to conceive who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. Method of contraception must be recorded in the case report file.
- Individual has a condition the study physician believes would interfere with the participant's ability to provide informed consent, comply with his responsibilities during the study, which might confound the interpretation of the study results or put the person at undue risk.
- Medical conditions including an active peptic ulcer, inflammatory bowel disease, or gastrointestinal bleeding and any medical condition or prior gastrointestinal surgery that could influence absorption, metabolism or excretion of the study supplement.
- History or presence of significant, renal, hepatic, gastrointestinal, pulmonary, biliary, neurological or endocrine disorders.
- History or presence of cancer in the past 2 yrs, except for non-melanoma skin cancers (e.g. basal or squamous cell carcinoma of the skin).
- Clinically significant abnormal laboratory test results including but not limited to LDL-cholesterol ≥ 4.1mM, triglyceride levels ≥3.95mM, fasting creatinine ≥ 1.5 mg/dL, alanine transaminase or aspartate aminotransferase ≥ 1.5X the upper limit of normal.
- Currently being treated for angina, arrhythmia and/or congestive heart failure. History of myocardial infarction or stroke.
- Uncontrolled hypertension (resting systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg).
- Type 1 or 2 diabetes. Fasting glucose ≥ 100 mg/dL. HbA1c ≥ 6.0.
- If a smoker, subject smokes no more than 1 pack (20 cigarettes) daily.
- History (within 12 months) or current alcohol or substance abuse (no more than 14 consumptions per week; 1 consumption= 12 oz beer, 5 oz wine, 1.5 oz distilled spirits).
- Use of any lipid-altering medications (statins, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, over the counter and prescription formulations of niacin).
- Unstable use of thyroid medication. Stable, treated hypothyroidism is not an exclusion criteria.
- Use of any weight loss or lipid metabolism medication/supplement/program (including lipase inhibitors) within 1 month of study period OR weight gain or loss > 2 kg in the past 3 months.
- Currently taking fish oil or any other omega-3 or omega-6 polyunsaturated fatty acids (PUFA) supplement/drug within one month of Visit 1 and throughout the study. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, and sardines) more than 2X a month within one month of visit 1 and throughout the study period. Consumption (more than twice a month) of any EPA/DHA enriched foods (e.g. docosahexaenoic acid (DHA)-enriched eggs) within one month of Visit 1. Unwillingness to avoid all fish including shellfish and crustaceans throughout the study period.
- Use of alpha-linolenic acid-containing seeds and oils such as flax seed, chia seed, perilla seed, hemp, spirulina, walnut, mustard seed or black currant seeds/oil within one month of Visit 1 and throughout the study.
- Use of an investigational product within the previous 30 days.
- Has donated blood up to 4 weeks before the start of the study. Not willing to cease being a blood donor during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: High oleic sunflower oil (HOSO)
10 ml HOSO/day in a single dose, 28 days
|
Other Names:
|
|
Experimental: High dose Buglossoides oil
10 ml Buglossoides oil/day in a single dose, 28 days
|
Other Names:
|
|
Experimental: Medium dose Buglossoides oil
6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
|
Other Names:
Other Names:
|
|
Experimental: Low dose Buglossoides oil
3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma eicosapentaenoic concentration (EPA)
Time Frame: Day 28
|
Expressed as μmol/L plasma
|
Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma 20:4n-3
Time Frame: Day 28
|
Expressed as μmol/L plasma
|
Day 28
|
|
Plasma docosapentaenoic acid (DPA)
Time Frame: Day 28
|
Expressed as μmol/L plasma
|
Day 28
|
|
Plasma 20:4n-3, EPA and DPA individually as % of total fatty acids
Time Frame: Day 28
|
Day 28
|
|
|
Mononuclear cell 20:4n-3, EPA and DPA individually as % of total fatty acids
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: glucose
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: calcium
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: sodium
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: potassium
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: blood urea nitrogen
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: creatinine
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: alkaline phosphatase
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: aspartate aminotransferase
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: gamma-glutamyltransferase
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: total bilirubin
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: amylase
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: uric acid
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: albumin
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology: white blood cell count
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology: neutrophil count
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology: red blood cell count
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology:hemoglobin
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology: hematocrit
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology: platelet count
Time Frame: Day 28
|
Day 28
|
|
|
Fasting blood lipid profile: triglycerides
Time Frame: Day 28
|
Day 28
|
|
|
Fasting blood lipid profile: total cholesterol
Time Frame: Day 28
|
Day 28
|
|
|
Fasting blood lipid profile: low density lipoprotein cholesterol (LDL-c)
Time Frame: Day 28
|
Day 28
|
|
|
Fasting blood lipid profile: non-high density lipoprotein-cholesterol (non-HDL-c)
Time Frame: Day 28
|
Day 28
|
|
|
Fasting blood lipid profile: HDL-c
Time Frame: Day 28
|
Day 28
|
|
|
Fasting serum chemistry: chloride
Time Frame: Day 28
|
Day 28
|
|
|
Estimated glomerular filtration rate
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: mean corpuscular volume
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: mean corpuscular hemoglobin
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: mean corpuscular hemoglobin concentration
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: red cell distribution width
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: mean platelet volume
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: lymphocyte concentration
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: monocyte count
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: eosinophil count
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: basophil count
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: Immature granulocytes count
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: immature granulocytes (% white blood cell (WBC))
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: neutrophil (% WBC)
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: lymphocyte (% WBC)
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: monocytes (% WBC)
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: eosinophil (% WBC)
Time Frame: Day 28
|
Day 28
|
|
|
Fasting hematology profile: basophil (% WBC)
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: appearance
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: density
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: leukocyte esterase
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: nitrites
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: pH
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: protein
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: glucose
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: acetone
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: blood
Time Frame: Day 28
|
Day 28
|
|
|
Urinalysis: urobilinogen
Time Frame: Day 28
|
Day 28
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cytokine production following ex vivo stimulation: interferon-gamma
Time Frame: Day 28
|
Day 28
|
|
Cytokine production following ex vivo stimulation: interleukin-1beta
Time Frame: Day 28
|
Day 28
|
|
Cytokine production following ex vivo stimulation: interleukin-6
Time Frame: Day 28
|
Day 28
|
|
Cytokine production following ex vivo stimulation: interleukin-8
Time Frame: Day 28
|
Day 28
|
|
Cytokine production following ex vivo stimulation: interleukin-10
Time Frame: Day 28
|
Day 28
|
|
Cytokine production following ex vivo stimulation: interleukin-17A
Time Frame: Day 28
|
Day 28
|
|
Cytokine production following ex vivo stimulation: interleukin-23
Time Frame: Day 28
|
Day 28
|
|
Cytokine production following ex vivo stimulation: monocyte chemoattractant protein-1
Time Frame: Day 28
|
Day 28
|
|
Cytokine production following ex vivo stimulation: tumor necrosis factor-alpha
Time Frame: Day 28
|
Day 28
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- HC-NNHPD-213421
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.